Table 1 Baseline characteristics

From: Transdermal testosterone gel vs placebo in women with diminished ovarian reserve prior to in vitro fertilization: a randomized, clinical trial

Characteristics

Testosterone

(N = 134)

Placebo

(N = 154)

Age (years)

38.0 ± 3.5

38.1 ± 3.2

Age group, No. (%)

  

  <36

28 (20.9)

25 (16.2)

  36 – 39

48 (35.8)

70 (45.5)

  ≥40

58 (43.3)

59 (38.3)

BMI (kg/m2)

24.9 ± 4.6

24.2 ± 4.0

Current smoker, No. (%)

21 (15.7)

24 (15.6)

Current alcohol use, No. (%)

23 (17.2)

32 (20.8)

Median duration of infertility (IQR) (months)

30 (18–48)

24 (16–41)

Cause of infertility, No. (%)a

  

  Andrological

36 (26.9)

39 (25.3)

  Endometriosis

8 (6.0)

13 (8.4)

  Ovulatory disorders

24 (17.9)

27 (17.5)

  Tubal factor

9 (6.7)

7 (4.5)

  Idiopathic

21 (15.7)

18 (11.7)

  Age-related

28 (20.9)

39 (25.3)

  Poor responder

54 (40.3)

60 (39.0)

  Other

8 (6.0)

25 (16.2)

Number of previous IVF cycles, No. (%)

  

  0

20 (14.9)

22 (14.3)

  1

42 (31.3)

50 (32.5)

  2

27 (20.2)

41 (26.6)

  ≥3

45 (33.6)

41 (26.6)

Previous live birth, No. (%)

25 (18.7)

19 (12.3)

Previous pregnancy loss, No. (%)

40 (29.9)

53 (34.4)

Laboratory/imaging findings (screening visit)

  

  AFC (No.)

4 (3–6)

4 (3–6)

  AMH (ng/ml)

0.45 (0.24–0.71)

0.48 (0.21–0.85)

  FSH (IU/L)

9.3 (6.6–14.2)

9.9 (6.7–12.7)

  SHBG (nmol/L)

71.8 (49.9–100.0)

72.0 (49.9–95.0)

  T (nmol/L)b

0.62 (0.36–0.90)

0.77 (0.52–1.10)

  1. Data are presented as mean ± SD, median (interquartile range) or number (%).
  2. BMI body mass index, IVF in vitro fertilization, AFC antral follicle count, AMH anti-Müllerian hormone, FSH follicle stimulating hormone, SHBG sex hormone binding globulin, T testosterone.
  3. aMultiple causes of infertility could be selected, leading to a total >100%.
  4. bBaseline testosterone level recorded on the day of starting treatment, not at the screening visit.